← All Gh Research PLC filings

Gh Research PLC 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
GHRS
Gh Research PLC
20-F: GH Research Reports Strong Clinical Data, Lifts FDA Hold
GH Research PLC announced positive clinical trial results for its mebufotenin product candidates, GH001 and GH002, and the lifting of a clinical hold on its GH001 IND by the FDA.
NASDAQ
GHRS
Gh Research PLC
20-F/A: GH Research PLC Amends Annual Report, Highlights Strong Clinical Data for Depression Therapies Amidst FDA Clinical Hold and Funding Needs
GH Research PLC filed an amendment to its 2024 annual report, confirming robust Phase 2b clinical trial results for its lead depression candidate GH001, while navigating an ongoing FDA clinical hold and outlining future funding requirements.
NASDAQ
GHRS
Gh Research PLC
20-F: GH Research PLC Updates Share Option Plan and Discloses Insider Trading Policy in 20-F Filing
GH Research PLC's 20-F filing details updates to its share option plan, introduces an insider trading policy, and provides a comprehensive overview of the company's operations and financial standing.
NASDAQ
GHRS
Gh Research PLC
20-F: GH Research PLC Files 20-F Report: Details Financial Performance and Clinical Pipeline
GH Research PLC's 20-F filing outlines the company's financial status, ongoing clinical trials, and potential risks associated with its novel mebufotenin therapies.